N/A N=434 VAscular Closure for Cardiac Ablation Registry (VACCAR)
Atrial Fibrillation
Primary: Hemostasis — 9; 20; 7 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=488 Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device
Angioplasty, Transluminal, Percutaneous Coronary · Coronary Arteriosclerosis · Peripheral Arteriosclerosis
Primary: Time to Hemostasis (TTH) — 4.68; 4.38; 20.05 Minutes — p=<0.0001
N/A N=204 AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F ID
Surgical Wound
Primary: Time to Ambulation (TTA) — 2.8; 6.1 hours
N/A N=64 Patient Comfort With Vascular Closure
Vascular Closure
Primary: Mean Score on the Visual Analogue Scale — 0.63; 0.59; 2.94; 5.03 Scores on a Scale
N/A N=147 Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System
Vascular Closure
Primary: Freedom From Major Complications — 83 Participants
N/A N=106 Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial
Atrial Fibrillation · Atrial Flutter · Heart Block
Primary: Time to Achieve Hemostasis — 7; 11 Minutes
N/A N=12 Safety and Performance Study of Large Hole Vascular Closure Device
Percutaneous Closure of Arteriotomy in Common Femoral Artery
Primary: Major Vascular Complications Directly Related to Device — 0 percentage of participants
N/A N=420 RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)
Surgical Wound
Primary: Time to Hemostasis (TTH) — 21.4; 4.8 minutes
N/A N=52 VASCADE ANTEGRADE-PVD Post-Market Registry
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes
N/A N=109 Comparison of Percutaneous Closure to Manual Compression for Hemostasis
Atrial Fibrillation
Primary: Time to Hemostasis — 4.5; 10.7 seconds
N/A N=220 The Closer Trial: A Safety and Efficacy Study of the Rex Medical Vascular Sealing System
Surgical Wound
Primary: Time to Hemostasis — 1.78 minutes
Phase 4 N=240 AngioSeal Versus Radial Approach in Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: First Occurrence of Access Site Related Ischemic or Bleeding Complication — 16; 15 Participants
N/A N=168 AMBULATE Continued Access Protocol to Evaluate the Cardiva Mid-Bore Venous Vascular Closure System (VVCS)
Surgical Wound
Primary: Number of Participants With Overall Procedure Success - Effectiveness — 168 Participants
N/A N=50 Comparing Perclose to Statseal With Perclose in Transcatheter Aortic Valve Replacement Arteriotomy Closure
Arterial Occlusion · Cardiovascular Diseases · Hematoma
Primary: Time to Hemostasis — 5.11; 4.3 minutes
N/A N=263 MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study
Femoral Arteriotomy Closure
Primary: Time to Hemostasis — 65.4 seconds
N/A N=235 Post-Market Study of the St. Jude Medical Angio-Seal™ V-Twist Integrated Platform (VIP) Vascular Closure Device
Vascular Closure
Primary: The Percentage of Subjects Experiencing a Device or Procedure Related Major Vascular Complication — 2.8 % of subjects with MVCs — p=0.0029
N/A N=50 Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device
Femoral Arteriotomy Closure
Primary: Number of Participants With Major Complications — 3 Participants
N/A N=36 Perclose Multi-Access Duplex Ultrasound (DUS) Study
Arrhythmia
Primary: Number of Subjects With Major Vascular Complications by DUS Detection at Discharge — 0; 0; 0; 0 Participants
N/A N=75 Safety and Performance Study of Large Hole Vascular Closure Device FIV
Percutaneous CFA Arteriotomy Closure
Primary: Major Vascular Complications [Safety] — 0 Participants — p=<.0001
N/A N=326 ClosureFAST - Radiofrequency Great Saphenous Vein Treatment
Venous Reflux
Primary: Percentage of Limbs Without Vein Occlusion — 97.6 percentage of limbs
N/A N=242 VenaSeal Sapheon Closure System Pivotal Study (VeClose)
Great Saphenous Vein (GSV) With Venous Reflux Disease
Primary: Number of Participants With Complete Closure of the Target Vein at 3 Months — 107; 109 Participants — p=<0.0001
Phase 4 N=208 The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Venous Access-Site Closure
Cardiac Diagnostic Procedure · Cardiac Interventional Procedure · Femoral Access Site Closure
Primary: Assessment of Venous Thrombosis — 0; 0 Participants
N/A N=75 Caring for the Radial Artery Post-angiogram
Transradial Angiogram
Primary: Bleeding Requiring Intervention After Initial Hemostasis Achieved — 2; 6; 3 participants — p=0.25
N/A N=207 Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)
Cardiac Disease · Coronary Artery Disease
Primary: The Primary Safety Endpoint Will be the Combined Rate of Major Complications With in 30 +/- 7 Days Following the Percutaneous Coronary Intervention (PCI) Procedure. — 1…
Phase 4 N=252 The Bioseal Vascular Study
Cardiovascular Bleeding · Vascular Bleeding · Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 10 Minutes Following the Completion of Treatment Application. — 96; 88.2 percentage of patients
N/A N=500 MANTA Registry for Vascular Large-bore Closure
Femoral Arteriotomy Closure
Primary: Time to Hemostasis — 50 seconds
N/A N=47 X-Seal EU Post-Market Clinical Follow-Up Protocol
Femoral Arteriotomy Closure
Primary: Major Complications — 0; 0 Participants
N/A N=270 Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression
Venous Vascular Closure
Primary: Primary Safety Endpoint: Major Complications of the Target Limb Access Site Within 30 Days — 0; 1 limbs
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
Phase 4 N=69 ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.
Venous Reflux
Primary: Pain — 0.7; 1.9 units on a scale — p=<0.0001